CONCLUSION
It seems that PEL has different clinical scenarios which we still don’t
fully understand affecting both immunocompetent and immunosuppressed
patients, each with different epidemiologic features and different
prognosis. The role of chemotherapy treatment in our case is still to be
discovered as the patient decided not to abstain from active treatment.
Physicians should be aware of all clinical scenarios to offer the best
treatment option for their patients.
DECLARATIONS
- Consent for publication – Written informed consent was
obtained from the patient for publication of this case report and any
accompanying images.
- Availability of data and materials – The datasets used
and/or analyzed during the current study are available from the
corresponding author on reasonable request
- Competing interests – The authors have no conflicts of
interest to declare
- Funding - The authors have not declared a specific grant for
this research from any funding agency in the public, commercial, or
not-for-profit sectors.
- Authors’ contributions –OK, AA and MAK contributed to the
writing, editing, formatting of the main manuscript, and production of
the figures. EP, LL, and YT provided care to the patient and revised
the manuscript. All authors have contributed and met the criteria for
authorship.
- Acknowledgments – We would like to thank Izabel Ben Guy for
her help and contribution to the research
REFERENCE
- Carbone A, Gloghini A. PEL and HHV8-unrelated effusion lymphomas:
classification and diagnosis. Cancer . 2008;114(4):225-227.
doi:10.1002/cncr.23597
- Fassone L, Bhatia K, Gutierrez M, et al. Molecular profile of
Epstein-Barr virus infection in HHV-8-positive primary effusion
lymphoma. Leukemia . 2000;14(2):271-277.
doi:10.1038/sj.leu.2401651
- Chen J, Mehraj V, Szabo J, Routy B, Michel RP, Routy JP. Multiple
remissions of extracavitary primary effusion lymphoma treated with a
single cycle of liposomal doxorubicin in a patient infected with
HIV. Curr Oncol. 2018;25(6):e592-e596. doi:10.3747/co.25.4119
- Ota Y, Hishima T, Mochizuki M, et al. Classification of AIDS-related
lymphoma cases between 1987 and 2012 in Japan based on the WHO
classification of lymphomas, fourth edition. Cancer Med .
2014;3(1):143-153. doi:10.1002/cam4.178
- Li S, Bai L, Dong J, Sun R, Lan K. Kaposi’s Sarcoma-Associated
Herpesvirus: Epidemiology and Molecular Biology. Adv Exp Med
Biol . 2017;1018:91-127. doi:10.1007/978-981-10-5765-6_7
- Narkhede M, Arora S, Ujjani C. Primary effusion lymphoma: current
perspectives. Onco Targets Ther . 2018;11:3747-3754. Published
2018 Jun 28. doi:10.2147/OTT.S167392
- Lurain K, Polizzotto MN, Aleman K, et al. Viral, immunologic, and
clinical features of primary effusion lymphoma. Blood .
2019;133(16):1753-1761. doi:10.1182/blood-2019-01-893339
- Fan W, Bubman D, Chadburn A, Harrington WJ Jr, Cesarman E, Knowles DM.
Distinct subsets of primary effusion lymphoma can be identified based
on their cellular gene expression profile and viral
association. J Virol . 2005;79(2):1244-1251.
doi:10.1128/JVI.79.2.1244-1251.2005
- Arora N, Gupta A, Sadeghi N. Primary effusion lymphoma: current
concepts and management. Curr Opin Pulm Med .
2017;23(4):365-370. doi:10.1097/MCP.0000000000000384